Table 2.
Number of trials | |
---|---|
Randomisation | |
Randomised | 26 (57.8%) |
Single-arm | 19 (42.2%) |
Blinding status | |
Blinded | 10 (22.2%) |
Open-label | 35 (77.8%) |
PRO related endpoint type | |
Primary | 1 (2.2%) |
Key secondary | 2 (4.4%) |
Secondary or exploratory | 42 (93.3%) |